Observational studyESC heart failure2025
A pilot study on DNA methylation changes for non-invasive molecular diagnostics in heart failure.
Observational study in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05475028 (Network Medicine Approaches to Classify Patients Suffering Heart Failure in Relation to Left Ventricle Ejection Fraction), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Network Medicine Approaches to Classify Patients Suffering Heart Failure in Relation to Left Ventricle Ejection Fraction (HFpEF, HFmrEF, HFrEF) by Circulating CD4+ T Cell-derived DNA Methylation Signatures, Clinical Data, and Point-of-care Risk Calculators
Who cites it
2 citing papers in PubMed.
- DNA methylation mediates MBSR induced cardioprotection in patients after PCI.Scientific reports · 2026Article
- A pilot study on DNA methylation changes for non-invasive molecular diagnostics in heart failure.ESC heart failure · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsThe current therapeutic approach to ischaemic (IsHF) and non-ischaemic (NIsHF) heart failure (HF) mainly overlooks the underlying aetiology owing to a lack knowledge of the differential molecular pathways that contribute to HF with reduced ejection fraction (HFrEF). Alterations in myocardial DNA methylation levels have been identified as potential biomarkers for HF irrespective of its aetiology. Due to the limited availability of cardiac tissues in clinics, our goal is to determine if DNA methylation changes in circulating CD4 METHODS AND
resultsWe performed a post hoc network-oriented analysis of the original PRESMET clinical trial dataset (NCT05475028). Integrating epigenomic data obtained with the high-resolution reduced representation bisulfite sequencing (RRBS) platform and the left-ventricle interactome (protein-protein interaction map) we identified six differentially methylated CpG positions (DMPs), which were able to distinguish IsHF (n = 8) versus NIsHF (n = 4) patients with an area under the curve (AUC) > 0.8. Network-oriented DMPs were significantly hypomethylated in IsHF versus NIsHF and annotated to six genes, namely, cytoskeleton-associated protein 4 (CKAP4), carnitine palmitoyltransferase 1A (CPT1A), eukaryotic translation initiation factor 2 subunit beta (EIF2S2), spectrin beta (SPTB), synaptotagmin 6 (SYT6) and RAB11 family interacting protein 1 (RAB11FIP1) (P < 0.05). We found that the CD4
conclusionsWe demonstrate that circulating CD4
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.